RIGEL PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Cost of revenue | $19.6M | $18.6M | $7.1M | $1.7M | $1.1M |
| Selling, general & administrative | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M |
| Research and development | $33.3M | $23.4M | $24.5M | $60.3M | $65.2M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M |
| Interest expense | $7.3M | $7.9M | $6.9M | $3.7M | $4.9M |
| Pretax income | $121.8M | $18.4M | -$25.1M | -$58.6M | -$17.3M |
| Income tax expense | -$245.2M | $881,000 | $0 | — | $605,000 |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M |
| Balance Sheet | |||||
| Cash and equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M |
| Current assets | $240.2M | $135.1M | $99.3M | $115.9M | $154.5M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M |
| Current liabilities | $99.2M | $63.3M | $53.3M | $65.2M | $63.6M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M |
| Total debt | $52.5M | $60.0M | $60.0M | $40.0M | — |
| Stockholders' equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M |
| Cash Flow Statement | |||||
| Cash from operations | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M |
| Depreciation and amortization | $2.4M | $2.2M | $1.2M | $998,000 | $1.2M |
| Stock-based compensation | $12.7M | $12.4M | $8.8M | $12.4M | $9.5M |
| Capital expenditure | — | — | — | $450,000 | $627,000 |
| Free cash flow | — | — | — | -$74.2M | $5.3M |
Shares outstanding 18.5M · Free float 75.5%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.